All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
VivoCAR™ Anti-HMW-MAA (C21) h(CD28-41BB-CD3z) CAR saRNA drives the expression of the C21 clone via a high-efficiency saRNA system. For in vivo therapy, the C21 clone is highly valued for its high-affinity binding to the extracellular domain of CSPG4, providing superior target recognition in heterogeneous tumors. The saRNA platform achieves biological magnification through intracellular replication, resulting in potent CAR expression following in situ reprogramming, which is critical for providing a durable immune response against refractory and metastatic solid malignancies.
There are currently no customer reviews or questions for VivoCAR™ Anti-HMW-MAA (C21) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU90). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION